UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13D
 
Under the Securities Exchange Act of 1934
 
In Veritas Medical Diagnostics, Inc.
(Name of Issuer)

Common Stock, par value $.0001 per share
(Title of Class of Securities)

 
45324V105
(CUSIP Number)

Kenneth Orr
Triuph Small Cap Fund, Inc.
48 South Service Rd., Suite 100E
Melville, NY 11747
( 631) 465-2180
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 18, 2007
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [_]

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 

 
SCHEDULE 13D
 
CUSIP No.    45324V105
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Triumph Small Cap Fund, Inc.
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)  [_]
(b)  [_]
 
3
SEC USE ONLY
 
 
4
SOURCE OF FUNDS (See Instructions)
OO
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
[ Y]
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
New York
 
NUMBER OF
 
SHARES
 
BENEFICIALLY
 
OWNED BY
 
EACH
 
REPORTING
 
PERSON
 
WITH
7
SOLE VOTING POWER
34,040,120
8
SHARED VOTING POWER
0
9
SOLE DISPOSITIVE POWER
34,040,120
10
SHARED DISPOSITIVE POWER
0
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
34,040,120
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
[_]
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
39.6% (based on 86,058,457 shares of Common Stock issued and outstanding)  
 
14
TYPE OF REPORTING PERSON (See Instructions)
CO
 
 
Page 2

 
 
CUSIP No.    45324V105
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Kenneth Orr
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)  [_]
(b)  [_]
 
3
SEC USE ONLY
 
 
4
SOURCE OF FUNDS (See Instructions)
OO
 
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
[ Y]
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
 
NUMBER OF
 
SHARES
 
BENEFICIALLY
 
OWNED BY
 
EACH
 
REPORTING
 
PERSON
 
WITH
7
SOLE VOTING POWER
34,040,120 (1)
8
SHARED VOTING POWER
0
9
SOLE DISPOSITIVE POWER
34,040,120
10
SHARED DISPOSITIVE POWER
0
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
34,040,120
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
[_]
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
39.6% (based on 86,048,457 shares of Common Stock issued and outstanding)  
 
14
TYPE OF REPORTING PERSON (See Instructions)
IN
 
(i) Mr. Orr has sole voting and dispositive power over the shares held by Triumph Small Cap Fund, Inc.
 
 
Page 3

 

Item 1.    Security and Issuer

The title and class of equity securities to which this Schedule 13D relates is Common Stock, par value $.001 per share (the "Common Stock"), of InVeritas Medical Diagnostics, Inc., a Colorado corporation (the "Issuer"). The address of the principal executive offices of the Issuer is The Green House Beechwood Business Park North, Inverness, Scotland, IV2 3BL.

Item 2.    Identity and Background

(a) This statement is being filed jointly by Triumph Small Cap Fund, Inc. (“Triumph”) and Kenneth Orr (“Orr”) (collectively, the “Reporting Persons”).

(b) The business address of the Reporting Persons is 48 South Service, Rd., Suite 100E, Melville, NY 11747 .

(c) Triumph and Orr are engaged in the business of making investments.

(d) Neither of the Reporting Persons have during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanours).

(e) On November 10, 1999 the Securities and Exchange Commission filed a civil action in federal district court against Kenneth Orr, the President of the Reporting Person, and sixteen other defendants, charging Mr. Orr with violations of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Exchange Act of 1934 (SEC v. Curtis, et al., 99 Civ 7357 (E.D.N.Y)(“Curtis”). On September 13, 2002, the United States Court for the Eastern District of New York entered a Final Judgment of Permanent Injunction and Other Relief as to Mr. Orr in Curtis, permanently enjoining Orr from future violations of Section 17(a) of the Securities Act, and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, ordering Orr to disgorge $55,000 in ill-gotten gains, approximately $44,000 in prejudgment interest, and post-judgment interest, and ordering Orr to pay a civil penalty of $55,000. Orr consented to the entry of the final judgment without admitting or denying the allegations in the Commission's Complaint.   Additionally, on January 3, 2002, Orr pleaded guilty to one count of conspiracy to launder money. United States v. Orr, 99 CR 1019 (E.D.N.Y). On May 21, 2002, a judgment in the criminal case was entered against Orr. He was sentenced to three years of probation and ordered to pay a $3,000 fine . In December 2004, Mr. Orr consented to the entry of an Order Making Findings and Imposing Remedial Sanctions pursuant to Section 15(b) of the Securities Exchange Act of 1934. In connection therewith, Mr. Orr was barred from association with any broker or dealer, without reapplying. Any reapplication or reentry by Mr. Orr will be subject to applicable laws and regulations. Mr. Orr has determined not to reapply or seek reentry.

(f) Triumph is incorporated under the laws of the State of New York.

Item 3.    Source and Amount of Funds or Other Considerations

Pursuant to the terms of a Purchase and Assignment Agreement dated December 18, 2007 (the “Assignment Agreement”, Triumph acquired the rights to a 18% Secured Convertible Debenture (the “Convertible Debenture”) that was originally issued pursuant to a Securities Purchase Agreement, as amended, between Montgomery Equity Partners Ltd. (“Montgomery”) and the Issuer dated as of September 7, 2005. Triumph acquired all of the rights of Montgomery to (a) the Investor Registration Rights Agreement, dated September 7, 2005, between the Issuer and Montgomery, (b) the Security Agreement, dated September 7, 2005, between the Issuer and Montgomery, (c) the Pledge and Escrow Agreement dated September 7, 2005, by and among the Issuer, Montgomery and David Gonzalez (the “Escrow and Pledge Agreement”). Pursuant to the Pledge and Escrow Agreement, the Issuer pledged 25,685,000 shares of its common stock as security for full and prompt payment of the Issuer’s obligations under the Purchase Agreement. In consideration for the assignment of its rights, Triumph (i) issued a promissory note in the amount of $150,052 to Montgomery, (ii) agreed to transfer to Montgomery 150,000 shares of its common stock of the Issuer (post a reverse stock split which the Issuer intends to implement), and (iii) issued a warrant to Montgomery to purchase 50,000 shares of its common stock at a price of $1.00 per share. Subsequently, Triumph issued a notice of default to the Issuer under the 18% Secured Convertible and received the right to vote 25,685,000 shares of common stock which were held in escrow to secure the Issuer’s obligations to repay the Convertible Debenture. The 25,685,000 shares were deposited in escrow pursuant to the Escrow Agreement among Montgomery, Triumph and Sichenzia Ross Friedman Ference LLP.

 
Page 4

 
 
Item 4.    Purpose of Transaction

The Reporting Person acquired the securities referred to in this Schedule 13D for investment purposes and not with the purpose or effect of changing or influencing control of the Issuer. Depending on market conditions and other factors, the Reporting Person may purchase additional shares of Common Stock in the open market or in private transactions. Subject to the availability of Common Stock at prices deemed favorable by the Reporting Person, the Reporting Person's liquidity, the financial condition and results of operations of the Company, and general economic and market conditions prevailing at the time, the Reporting Person reserve the right to, and may in the future, purchase additional shares of Common Stock from time to time in the open market, through privately negotiated transactions, or otherwise.

The Reporting Person has voted to approve the sale of substantially all of the assets of the Issuer’s wholly owned subsidiaries, IVMD (UK) Limited and Jopejo Limited pursuant to a Stock Purchase Agreement dated as of December 18, 2007 by and among the Issuer, its wholly owned subsidiaries and Medical Diagnostic Innovations Ltd. (the “Stock Purchase Agreement”). In addition, the Reporting Person has entered into a Purchase and Assignment Agreement with each of Longview Fund, L.P. and Whalehaven Capital Fund Limited, pursuant to which the Reporting Person acquired the rights to certain Secured Convertible Debentures. In addition, the Reporting Person holds certain other Debentures and Promissory Notes issued by the Issuer which it may convert into shares of common stock of the Issuer.
 
Item 5.    Interest in Securities of the Issuer

The Reporting Persons currently own 34,040,120 shares of common stock of the Issuer , which represents 39.6% of the Issuer’s common stock based on 86,058,457 shares of common stock issued and outstanding. Orr has the sole power to vote or direct the vote, and to dispose or direct the disposition of such shares.  

Except as set out above, the Reporting Persons have not effected any other transaction in any securities of the Issuer in the past sixty days.

Item 6.    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Pursuant to the terms of a Purchase and Assignment Agreement dated December 18, 2007 (the “Assignment Agreement”, Triumph acquired the rights to a 18% Secured Convertible Debenture (the “Convertible Debenture”) that was originally issued pursuant to a Securities Purchase Agreement, as amended, between Montgomery Equity Partners Ltd. (“Montgomery”) and the Issuer dated as of September 7, 2005. Triumph acquired all of the rights of Montgomery to (a) the Investor Registration Rights Agreement, dated September 7, 2005, between the Issuer and Montgomery, (b) the Security Agreement, dated September 7, 2005, between the Issuer and Montgomery, (c) the Pledge and Escrow Agreement dated September 7, 2005, by and among the Issuer, Montgomery and David Gonzalez (the “Escrow and Pledge Agreement”). Pursuant to the Pledge and Escrow Agreement, the Issuer pledged 25,685,000 shares of its common stock as security for full and prompt payment of the Issuer’s obligations under the Purchase Agreement. In consideration for the assignment of its rights, Triumph (i) issued a promissory note in the amount of $150,052 to Montgomery, (ii) agreed to transfer to Montgomery 150,000 shares of its common stock of the Issuer (post a reverse stock split which the Issuer intends to implement), and (iii) issued a warrant to Montgomery to purchase 50,000 shares of its common stock at a price of $1.00 per share. Subsequently, Triumph issued a notice of default to the Issuer under the 18% Secured Convertible and received the right to vote 25,685,000 shares of common stock which were held in escrow to secure the Issuer’s obligations to repay the Convertible Debenture. The 25,685,000 shares were deposited in escrow pursuant to the Escrow Agreement among Montgomery, Triumph and Sichenzia Ross Friedman Ference LLP.

Item 7.    Material to Be Filed as Exhibits

Exhibit Number
 
Description
99.1
 
Purchase and Assignment Agreement dated December 18, 2007
 
 
Page 5

 
SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:   January 17, 2008
     
  Triumph Small Cap Fund, Inc.
 
 
 
 
 
 
  By:   /s/ Kenneth Orr
 
Name: Kenneth Orr
  Title: President
   
   
  /s/ Kenneth Orr
  Kenneth Orr
 
 
Page 6

 
PURCHASE AND ASSIGNMENT AGREEMENT
 
THIS PURCHASE AND ASSIGNMENT AGREEMENT   (this " Agreement "), is made on December 18, 2007, among Montgomery Equity Partners Ltd. (“Montgomery” or the “Assignor”), Triumph Small Cap Fund, Inc. (the “ Assignee ”), and In Veritas Medical Diagnostics, Inc. (the " Company ").
 
WHEREAS , Assignor is the legal and beneficial owner of those certain Secured Convertible Debentures set forth on Schedule I attached hereto (collectively, the “Debentures”), of the Company issued on the dates and in the amounts as indicated on Schedule I.
 
WHEREAS , the Debentures were originally issued pursuant to a Securities Purchase Agreement, as amended, between the Assignor and the Company dated as of September 7, 2005 (the “ Securities Purchase Agreement ”);
 
WHEREAS , Assignor desires to assign to Assignee and Assignee desires to accept from Assignor the Debentures on the basis of the representations, warranties and agreements contained in this Agreement, and upon the terms but subject to the conditions set forth herein;
 
WHEREAS , Assignor desires to assign to Assignee and Assignee desires to assume from Assignor, its rights as a holder of the Debentures under (a) the Securities Purchase Agreement, (b) the Investor Registration Rights Agreement, dated September 7, 2005, between the Company and Montgomery (the " Registration Rights Agreement "), (c) the Security Agreement, dated September 7, 2005, between the Company and Montgomery (“ Security Agreement ”), (d) the Pledge and Escrow Agreement dated September 7, 2005, by and among the Company, Montgomery and David Gonzalez (the “ Pledge Agreement ”) (e) all related documents under which the Assignor has rights or interests in the Debentures, and (f) all amendments to the documents referred to in (a) through (e) in this paragraph (collectively, the " Transaction Documents "), on the basis of the representations, warranties and agreements contained in this Agreement, and upon the terms but subject to the conditions set forth herein;
 
WHEREAS ,
 
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the adequacy of which is hereby acknowledged, the parties hereto agree as follows:
 
1.   Purchase Price
 
 
a)
As consideration for assignment set forth herein of the Debentures owned by Montgomery, the Assignee agrees to (the “ Purchase Price ”): (A) pay the aggregate sum of One Hundred Fifty Thousand and Fifty Two ($150,052) Dollars which shall be paid by the issuance of a promissory note issued by the Assignee to Montgomery; (B) transfer to Montgomery One Hundred and Fifty Thousand (150,000) shares of common stock of the Company which are held by the Assignee (the “Shares”), post a reverse stock split which is contemplated by the Company; and (C) issue to Montgomery a warrant to purchase 50,000 shares of its common stock at a price of $1.00 per share (the “Warrants”).
 
 
1

 
2.   Assignment .
 
 
a)
On the Closing Date (as set forth below), for the payment of the Purchase Price the Assignor hereby absolutely, irrevocably and unconditionally sells, assigns, conveys, contributes and transfers to the Assignee (a) all of the Debentures owned by the Assignor and all of its rights and benefits thereunder and conferred therein, including without limitation the right to collect from the Company the principal amounts outstanding thereunder, plus accrued but unpaid interest as indicated on Schedule I, and (b) all rights and interests that Assignor has under the Transaction Documents and the Assignee accepts such assignment.
     
  b) Closing Procedures . The closing of the assignment contemplated hereunder shall take place simultaneously with the date of execution hereof (the “ Closing Date ”) or such other date as mutually agreed by the parties hereto, at the offices of Montgomery. On the Closing Date, the following shall take place:    
 
 
i)
The Assignee shall deliver the Promissory Note to the Assignor;
 
 
ii)
The Assignee shall deliver a warrant agreement (the “Warrant”) to the Assignor that is (i) acceptable in form to Assignor and (ii) provides Assignor with the purchase right set forth in Section 1(a)(C) of this Agreement;
 
 
iii)
The Assignee shall deliver to Sichenzia Ross Friedman Ference LLP (“SRFF”) 50,000 shares of common stock to be held in escrow to be issued to Montgomery upon exercise of the Warrants;
 
 
iv)
Immediately upon receipt of the items set forth in 1(b)(i) hereof, the Assignor shall deliver to SRFF, as escrow agent, the original Debentures as set forth on Schedule I and shall cause, David Gonzalez, the Escrow Agent pursuant to the Pledge Agreement, to deliver the Transfer Documents, as such term is defined in the Pledge Agreement, to SRFF.
 
3.   Additional Documents . The Assignor and Assignee agree to take such further action and to execute and deliver, or cause to be executed and delivered, any and all other documents which are, in the reasonable opinion of their counterparty, necessary to carry out the terms and conditions of this Assignment.
 
4.   Effective Date and Counterpart Signature . The transactions contemplated hereby shall become effective simultaneously with the closing of the Stock Purchase Agreement among the Company and Medical Diagnostic Innovations Ltd. but in no event not later than sixty (60) days from the date hereof. In the event that the transactions contemplated by the Stock Purchase Agreement are not consummated within sixty (60) days from the date hereof, this Agreement shall become null and void. This Agreement, and acceptance of same, may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Confirmation of execution by telex or by telecopy or telefax of a facsimile signature page shall be binding upon that party so confirming.
 
 
2

 
5.   Representations and Warranties of the Assignee .
 
(a)   Organization; Authority . The Assignee is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with full right, corporate, partnership or other applicable power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations thereunder, and the execution, delivery and performance by the Assignee of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of the Assignee. This Agreement, when executed and delivered by the Assignee, will constitute a valid and legally binding obligation of the Assignee, enforceable against the Assignee in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (c) to the extent the indemnification provisions contained herein may be limited by federal or state securities laws.

(b)   Ownership .   Assignee owns and is conveying to Assignee all of its rights, title and interests to the Shares and the Warrant, free and clear of all liens, mortgages, pledges, security interests, encumbrances or charges of any kind or description

(c)   Investment Experience; Access to Information and Preexisting Relationship . The Assignee (a) either alone or together with its representatives, has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of this investment and make an informed decision to so invest, and has so evaluated the risks and merits of such investment, (b) has the ability to bear the economic risks of this investment and can afford a complete loss of such investment, (c) understands the terms of and risks associated with the acquisition of the Debentures, including, without limitation, a lack of liquidity, price transparency or pricing availability and risks associated with the industry in which the Company operates, (d) has had the opportunity to review such disclosure regarding the Company, its business, its financial condition and its prospects as the Assignee has determined to be necessary in connection with the Assignment of the Debentures, including, without limitation, the Company’s Annual Report on Form 10-K (or substantially equivalent form) for its most recently completed fiscal year, the Company’s Quarterly Reports on Form 10-Q (or substantially equivalent form) for the fiscal quarters since the end of such completed fiscal year, and the Company’s Current Reports on Form 8-K (or substantially equivalent form) since the end of such completed fiscal year, each as amended .

 
3

 
(d)   Assignee Status . At the time the Assignee was offered the Debentures, it was, and as of the date hereof it is, an “ accredited investor ” as that term is defined in Rule 501(a) of Regulation D under the Securities Act. The Assignee is not, and is not required to be registered as, a broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended (the “ Exchange   Act ”).

(e)   Restrictions on Transfer . The Assignee understands that (a) the Debentures (including the shares of Common Stock underlying such Debentures) have not been registered under the Securities Act or the securities laws of any state, (b) the Debentures (including the shares of Common Stock underlying such Debenture) are and will be “ restricted securities ” as said term is defined in Rule 144 of the Rules and Regulations promulgated under the Securities Act (“ Rule   144 ”), (c) the Debentures (including the shares of Common Stock underlying such Debenture) may not be sold, pledged or otherwise transferred unless a registration statement for such transaction is effective under the Securities Act and any applicable state securities laws, or unless an exemption from such registration provisions is available with respect to such transaction, and (d) the Debentures (including the shares of Common Stock underlying such Debentures) will bear a legend substantially as set forth below:

NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
 
(f)   General Solicitation . The Assignee is not accepting such Assignment as a result of any advertisement, article, notice or other communication regarding the Debentures published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

(g)   No Conflicts; Advice . Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby, does or will violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge or other restriction of any government, governmental agency, or court to which the Assignee is subject or any provision of its organizational documents or other similar governing instruments, or conflict with, violate or constitute a default under any agreement, credit facility, debt or other instrument or understanding to which the Assignee is a party. The Assignee has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with the Assignment of the Debenture.

 
4

 
(h)   No Litigation . There is no action, suit, proceeding, judgment, claim or investigation pending, or to the knowledge of the Assignee, threatened against the Assignee which could reasonably be expected in any manner to challenge or seek to prevent, enjoin, alter or materially delay any of the transactions contemplated by this Agreement.

(i)   Consents . No authorization, consent, approval or other order of, or declaration to or filing with, any governmental agency or body or other Person is required for the valid authorization, execution, delivery and performance by the Assignee of this Agreement and the consummation of the transactions contemplated hereby.

(j)   Stop Transfer Notices . The Assignee agrees that, in order to ensure compliance with the restrictions referred to herein, appropriate “stop transfer” instructions may be issued to the Company’s transfer agent.

(k)   Assignor’s Relationship with Company . The Assignor has informed the Assignee that the Assignor and its affiliates have and have had a variety of relationships with the Company. The Assignor and its affiliates may have obtained or be in possession of, or later may come into possession of, material, non-public, confidential information concerning the Company and their respective subsidiaries and affiliates, their respective assets or the Debentures (or the common stock into which such Debentures are convertible) and are precluded from sharing such information with the Assignee. The Assignor and its affiliates have advised the Assignee that such information may be indicative of a value of the Debentures that is substantially less than or greater than the consideration for which they are being assigned hereunder. The Assignee is experienced, sophisticated and knowledgeable in trading in publicly-traded and other securities of companies and understands the disadvantage to which he may be subject on account of the disparity of information as between it and the Assignor. The Assignee expressly releases the Seller and each of its affiliates and their respective officers, directors, members, managers, partners, equity holders and employees (collectively, the " Released Parties ") from any and all liabilities arising from the Assignor’s failure to have access to or review such confidential information and otherwise in respect of the transaction that is the subject of this Agreement (the “ Transaction ”), and agrees to make no claim against the Released Parties in respect of the Transaction. The Assignor is relying on this Paragraph 5(k) in assigning the Debentures for the consideration set forth herein, and would not engage in the transaction of which the assignment of the Debentures is part in the absence of this Paragraph 5(k).
 
6.   Representations and Warranties of the Assignor
 
(a)   Organization; Authority . The Assignor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with full right, corporate, partnership or other applicable power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations thereunder, and the execution, delivery and performance by the Assignor of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of the Assignor. This Agreement, when executed and delivered by the Assignor, will constitute a valid and legally binding obligation of the Assignor, enforceable against the Assignor in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors' rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (c) to the extent the indemnification provisions contained herein may be limited by federal or state securities laws.
 
 
5

 
(b)   Ownership .   Subject to the terms of the Escrow Agreement of even date herewith governing their deposit into escrow, Assignor owns and is conveying to Assignee all of its rights, title and interests to the assigned Debentures, free and clear of all liens, mortgages, pledges, security interests, encumbrances or charges of any kind or description.
 
(c)   No Consents, Approvals, Violations or Breaches . Neither the execution and delivery of this Agreement by the Assignor, nor the consummation by Assignor of the transactions contemplated hereby, will (i) require any consent, approval, authorization or permit of, or filing, registration or qualification with or prior notification to, any governmental or regulatory authority under any law of the United States, any state or any political subdivision thereof applicable to Assignor, (ii) violate any statute, law, ordinance, rule or regulation of the United States, any state or any political subdivision thereof, or any judgment, order, writ, decree or injunction applicable to Assignor or any of Assignor’s properties or assets, the violation of which would have a material adverse effect upon Assignor, or (iii) violate, conflict with, or result in a breach of any provisions of, or constitute a default (or any event which, with or without due notice or lapse of time, or both, would constitute a default) under, or result in the termination of, or accelerate the performance required by, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument or obligation to which Assignor is a party or by which Assignor or any of Assignor’s properties or assets may be bound which would have a material adverse effect upon Assignor.

7.   Governing Law; Submission to Jurisdiction . THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW JERSEY, WITHOUT REGARD TO CONFLICT OF LAW PRINCIPLES. EACH PARTY AGREES THAT ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING IN ANY WAY TO THIS AGREEMENT SHALL BE BROUGHT IN A U.S. FEDERAL OR STATE COURT OF COMPETENT JURISDICTION SITTING IN HUDSON COUNTY, IN THE STATE OF NEW JERSEY. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY CONSENTS TO THE JURISDICTION OF SUCH COURT AND HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY DEFENSE OF AN INCONVENIENT FORUM OR A LACK OF PERSONAL JURISDICTION TO THE MAINTENANCE OF ANY ACTION OR PROCEEDING AND ANY RIGHT OF JURISDICTION OR VENUE ON ACCOUNT OF THE PLACE OF RESIDENCE OR DOMICILE OF ANY PARTY HERETO. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
 
 
6

 
8.   Amendments . No provision hereof may be waived or modified other than by an instrument in writing signed by the party against whom enforcement is sought.
 
9.   Severability . If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.
 
10.   Consent . Pursuant to Section 9(g) of the Securities Purchase Agreement, the Company consents to the assignment of the Debentures.
 
11.   Release . Upon the execution of this Agreement by the Assignor, the Assignee, and the Company and completion of the obligations contained in Paragraph 1 and 2 :
 
 
a)
any and all commitments, rights and obligations to the Company by the Assignor set forth under the Transaction Documents shall be terminated, and all amounts due and payable by the Company to the Assignor under the Transaction Documents shall be deemed to be paid in full and complete satisfaction of all outstanding obligations;
 
 
b)
the Assignee, on behalf of itself and on behalf of its affiliates, and its and their respective officers, directors, partners, general partner, limited partners, shareholders, associates, employees, members, parents, subsidiaries, affiliates, agents, predecessors, successors and assigns (collectively, the " Assignee Affiliated Parties "), hereby releases and forever discharges the Assignor and their affiliates, and their respective officers, directors, partners, general partner, limited partners, shareholders, associates, employees, members, parents, subsidiaries, affiliates, agents, predecessors, successors and assigns (including, without limitation, Yorkville Advisors, LLC and its respective officers, directors, partners, general partners, limited partners, shareholders, associates, employees, members, parents, subsidiaries, affiliates, agents, predecessors, successors and assigns) (collectively, the " Assignor Affiliated Parties "), of and from any and all claims, complaints, demands, obligations, causes of action, choices in action and/or damages whatsoever, at law or in equity (collectively, "Claims") which such parties ever had or now have based on or arising out of events or circumstances occurring, or actions taken or failed to be taken, in each case, that are known or unknown by an Assignee or an Assignee Affiliated Party as of the date hereof, in connection with the Debentures.
 
 
7

 
 
 
c)
each of the Assignees, on its own behalf and on behalf of the Assignee Affiliated Parties, covenants, to the maximum extent permitted by law, that neither it nor any Assignee Affiliated Party shall at any time hereafter file, commence or maintain or authorize any third party to file, commence or maintain on its behalf, any suit, action or proceeding before any federal, state or local court, administrative body, agency, authority or arbitral organization or other tribunal against any of the Assignor Affiliated Parties with respect to any Claims released pursuant to Paragraph 10(b).
 
 
d)
the Company, on behalf of itself and on behalf of its affiliates, and its and their respective officers, directors, partners, general partner, limited partners, shareholders, associates, employees, members, parents, subsidiaries, affiliates, agents, predecessors, successors and assigns, and anyone claiming by or through any of the foregoing (collectively, the " Company Affiliated Parties "), hereby releases and forever discharges the Assignor and the Assignor Affiliated Parties of and from any and all Claims which such parties ever had or now have based on or arising out of events or circumstances occurring, or actions taken or failed to be taken, in each case, that are known or unknown by the Company or a Company Affiliated Party as of the date hereof, in connection with the Debentures .
 
 
e)
the Company, on its own behalf and on behalf of the Company Affiliated Parties, covenants, to the maximum extent permitted by law, that neither it nor any Company Affiliated Party shall at any time hereafter file, commence or maintain or authorize any third party to file, commence or maintain on its behalf, any suit, action or proceeding before any federal, state or local court, administrative body, agency, authority or arbitral organization or other tribunal against the Assignor or the Assignor Affiliated Parties with respect to any Claims released pursuant to Paragraph 10 (d).
 
 
f)
the Assignor, on behalf of itself and the Assignor Affiliated Parties, hereby releases and forever discharges the Assignee Parties, the Assignee Affiliated Parties, the Company and the Company Affiliated Parties of and from any and all Claims, known or unknown, which such parties ever had, now have or may hereafter have based on or arising out of the Debentures.
 
 
g)
the Assignor, on its own behalf and on behalf of the Assignor Affiliated Parties, covenants, to the maximum extent permitted by law, that neither it nor any Assignor Affiliated Party shall at any time hereafter file, commence or maintain or authorize any third party to file, commence or maintain on its behalf, any suit, action or proceeding before any federal, state or local court, administrative body, agency, authority or arbitral organization or other tribunal against the Assignee Parties, the Assignee Affiliated Parties, the Company or the Company Affiliated Parties with respect to any Claims released pursuant to Paragraph 10(f).
 
IN WITNESS WHEREOF , the parties hereto have executed this Agreement the day and year first above written.
 
 
8

 
ASSIGNOR      

MONTGOMERY EQUITY PARTNERS, L.P.


By: /s/ Mark Angelo                                                                   
Name: Mark Angelo
Title: Portfolio Manager of Yorkville Advisors, LLC, the
Investment Manager of Montgomery Equity Partners, L.P.



ASSIGNEE

TRIUMPH SMALL CAP FUND, INC.


By:____ /s/ Kenneth Orr __________________________
Name: Kenneth Orr  
Title: President  



AGREED AND ACKNOWLEDGED

IN VERITAS MEDICAL DIAGNOSTICS, INC.
 
By: /s/ Martin Thorp  
Name: Martin Thorp
Title: Chief Financial Officer

 
 
9

 


SCHEDULE I
 
 
 
 
 
10